Hexarelin

What is Hexarelin?#

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS) with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of approximately 887.0 Da. It belongs to the growth hormone releasing peptide (GHRP) family, a class of synthetic peptides that stimulate pituitary growth hormone (GH) release through activation of the growth hormone secretagogue receptor type 1a (GHS-R1a), later identified as the ghrelin receptor.

Hexarelin was developed as a structural optimization of earlier GHRPs, incorporating D-amino acid substitutions and N-methylation to enhance receptor binding potency and resistance to enzymatic degradation. Among the GHRP family members -- including GHRP-2, GHRP-6, and ipamorelin -- hexarelin is generally considered to elicit the most robust acute GH release on a per-dose basis. Its molecular formula is C47H58N12O6, and its CAS registry number is 140703-51-1.

Beyond its role as a GH secretagogue, hexarelin has attracted considerable research interest for its cardiovascular protective properties. These cardioprotective effects appear to be mediated through a GH-independent mechanism involving the CD36 scavenger receptor, distinguishing hexarelin from other GHS peptides and suggesting a broader pharmacological profile than initially appreciated.

Hexarelin has progressed to Phase 2 clinical trials in humans, generating data on its GH-releasing efficacy, cardiovascular effects, and safety profile, though it has not advanced to approval for any therapeutic indication.

Mechanism of Action#

GHS-R1a Receptor Activation and GH Release#

Hexarelin exerts its primary GH-releasing effect through binding to the GHS-R1a receptor, a G protein-coupled receptor (GPCR) predominantly expressed in the hypothalamus and anterior pituitary gland. Activation of GHS-R1a in somatotroph cells of the anterior pituitary triggers phospholipase C (PLC) signaling, leading to inositol trisphosphate (IP3)-mediated calcium release from intracellular stores and subsequent calcium influx through voltage-gated calcium channels. The resulting rise in intracellular calcium stimulates exocytosis of GH-containing secretory granules.

At the hypothalamic level, hexarelin stimulates the release of growth hormone-releasing hormone (GHRH) from arcuate nucleus neurons and suppresses somatostatin release, creating a permissive hormonal environment for pituitary GH secretion. This dual mechanism -- direct pituitary stimulation combined with hypothalamic modulation -- contributes to the robust GH response observed with hexarelin administration.

The GHS-R1a was identified as the endogenous receptor for ghrelin, the 28-amino-acid acylated peptide produced primarily by gastric oxyntic cells. Hexarelin thus functions as a synthetic mimetic of ghrelin's GH-releasing activity, though the two ligands differ in their receptor binding kinetics, downstream signaling bias, and secondary pharmacological activities.

CD36-Mediated Cardioprotection#

A distinctive feature of hexarelin among GHS peptides is its binding to the CD36 scavenger receptor, a class B scavenger receptor expressed on cardiomyocytes, macrophages, endothelial cells, and adipocytes. The CD36-mediated effects of hexarelin appear to be independent of GHS-R1a activation and GH release, as demonstrated in studies using GH-deficient animal models and GHS-R1a knockout systems.

Through CD36 engagement, hexarelin has been shown to activate peroxisome proliferator-activated receptor gamma (PPAR-gamma) signaling in cardiac tissue. PPAR-gamma activation promotes anti-inflammatory gene expression, reduces oxidative stress, and modulates lipid metabolism in cardiomyocytes. In experimental models of myocardial ischemia-reperfusion injury, hexarelin pretreatment reduced infarct size, preserved left ventricular function, and attenuated cardiomyocyte apoptosis through CD36-dependent pathways.

Additional cardioprotective mechanisms attributed to hexarelin include inhibition of cardiac fibrosis through suppression of transforming growth factor beta (TGF-beta) signaling, modulation of mitochondrial function in cardiomyocytes, and reduction of oxidized low-density lipoprotein (oxLDL) uptake by macrophages within atherosclerotic lesions.

Synergy with GHRH and Neuroendocrine Effects#

When co-administered with GHRH, hexarelin produces a synergistic GH response that exceeds the sum of individual responses. This synergy arises because hexarelin and GHRH act through distinct receptors and signaling mechanisms at the pituitary level, and hexarelin additionally modulates hypothalamic somatostatin tone. The synergistic response has been exploited diagnostically to assess pituitary GH reserve.

Hexarelin also stimulates modest increases in prolactin, cortisol (via ACTH), and aldosterone secretion, reflecting its activity at hypothalamic sites beyond the GH axis. These secondary hormonal effects are generally dose-dependent and more pronounced than those observed with GHRP-2 or ipamorelin.

Therapeutic Applications and Clinical Evidence#

Phase 2 Clinical Trials in GH Deficiency#

Phase 2 clinical trials have evaluated hexarelin in both GH-deficient adults and healthy volunteers. Intravenous administration of hexarelin at doses ranging from 0.5 to 2.0 micrograms per kilogram body weight produced dose-dependent increases in serum GH, with peak GH levels occurring approximately 15 to 30 minutes post-injection. In GH-deficient patients, hexarelin was effective in stimulating GH release, though the magnitude of response was attenuated compared to healthy controls, reflecting reduced somatotroph reserve.

Repeated daily administration studies revealed attenuation of the GH response over time, with significant blunting observed within one to two weeks of continuous use. This desensitization phenomenon represents a notable limitation of hexarelin and has been attributed to GHS-R1a downregulation and increased somatostatin tone. Intermittent dosing protocols partially preserved the GH response, suggesting that receptor recovery occurs during treatment-free intervals.

Cardiovascular Studies#

Human studies have explored hexarelin's cardiovascular effects in patients with cardiac conditions. In patients with ischemic heart disease, hexarelin administration improved left ventricular ejection fraction and regional wall motion abnormalities in preliminary assessments. Studies in patients with GH deficiency, who frequently exhibit adverse cardiovascular risk profiles, demonstrated improvements in cardiac performance parameters following hexarelin treatment.

Animal models have provided more extensive cardiovascular data. In rat models of myocardial infarction, hexarelin reduced infarct size by 25 to 40 percent when administered before or shortly after ischemic injury. These effects were reproduced in CD36-expressing but not CD36-knockout animals, confirming the receptor dependence of cardioprotection.

Comparison with GHRP-6 and GHRP-2#

Within the GHRP family, hexarelin, GHRP-2, and GHRP-6 share the GHS-R1a binding mechanism but differ in potency, selectivity, and side-effect profiles. Hexarelin generally produces the highest peak GH levels but also shows greater stimulation of cortisol and prolactin compared to GHRP-2. GHRP-6 is notable for its more pronounced appetite-stimulating effects due to stronger ghrelin-mimetic activity.

GHRP-2 is often considered to have the most favorable selectivity profile, with potent GH release and minimal effects on cortisol, prolactin, and appetite. Ipamorelin, a more recently developed GHS peptide, offers even greater selectivity for GH release with minimal secondary hormonal effects but lacks hexarelin's cardioprotective CD36 activity.

The desensitization observed with hexarelin appears to be a class effect shared by other GHRPs, though the rate and degree of attenuation may vary among compounds and dosing regimens.

Evidence Gaps and Limitations#

Desensitization and Tachyphylaxis#

The most significant pharmacological limitation of hexarelin is the rapid desensitization of the GH response during sustained administration. Clinical data consistently show attenuation of peak GH levels within days to weeks of daily dosing. The mechanisms underlying this tachyphylaxis are incompletely understood and may involve GHS-R1a internalization, altered hypothalamic somatostatin regulation, or feedback through elevated IGF-1 levels. Without a validated dosing strategy that preserves long-term efficacy, the clinical utility of hexarelin as a chronic GH-stimulating therapy remains uncertain.

Limited Late-Stage Clinical Data#

Despite promising Phase 2 results, hexarelin has not progressed to Phase 3 clinical trials for any indication. The absence of large-scale, controlled efficacy and safety data limits definitive conclusions about its therapeutic potential. The development of non-peptide GHS-R1a agonists (such as MK-0677/ibutamoren) and the approval of tesamorelin (a GHRH analog) for specific indications may have reduced commercial interest in advancing hexarelin through later-stage development.

Incomplete Cardiovascular Translation#

While the CD36-mediated cardioprotective effects of hexarelin are well-documented in preclinical models, the translation of these findings to human cardiovascular endpoints remains incomplete. The human cardiovascular data are limited to small, short-term studies without hard clinical endpoints such as myocardial infarction rates or cardiovascular mortality. The relative contributions of GH-dependent versus CD36-dependent mechanisms to any observed cardiac benefits in humans have not been clearly delineated.

Secondary Hormonal Effects#

Hexarelin's stimulation of cortisol and prolactin release, while generally modest and transient, represents a selectivity concern for any potential chronic therapeutic use. Sustained cortisol elevation could produce adverse metabolic effects, while prolactin elevation could have reproductive and other endocrine consequences. These secondary effects distinguish hexarelin from more selective GHS compounds and may influence risk-benefit assessments.

Regulatory Status#

Hexarelin is not approved for therapeutic use in any jurisdiction. It is classified as a research compound and is available for investigational purposes only. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of growth hormone secretagogues.

Key Research Findings#

Hexarelin protects the heart from acute myocardial ischemia-reperfusion injury through CD36 scavenger receptor, published in American Journal of Physiology - Heart and Circulatory Physiology (Bhatt N et al., 2005):

• Reduced infarct size by 25-40% in ischemia reperfusion models

Related Reading#

• Hexarelin research studies and evidence
• Hexarelin dosing protocols
• Hexarelin side effects profile
• GHRP-2 research guide
• Ibutamoren (MK-677) research guide